

European Partnership for Personalised Medicine calling for national and regional involvement

An information event by ICPerMed and ERA PerMed

May 31, 2021




Involvement of Industry


Ejner Moltzen, Innovation Fund Denmark

(Member of ICPerMed/ERA PerMed Preparatory Group)

All players are needed to bring PM alive



The role of industry/biotech in R&D



Industry, both large companies and biotech, play a special role in developing treatments, both alone and in public-private partnerships.

Public-private partnerships

- The scientific and technical challenges, that must be overcome to develop the new and improved personalised treatments are substantial
- The competencies of all involved stakeholders must be used and combined optimally to progress the field
- Thus, alliances between public research institutions/hospitals and industrial/biotech/private players are necessary.

Public-private partnerships

- There are many successful examples:
 - Many ERA PerMed projects are involving both public and private participants
 - Very rapid development of Covid-19 vaccines was successful due to public-private partnerships
 - The Innovative Medicines Initiative, IMI, co-funded by the EC and EFPIA, has run over 160 public-private life science projects over the last 10 years totaling an investment of over €3.5 bn
- The successor to IMI under Horizon Europe is under way: the Innovative Health Initiative (IHI)

EP PerMed and industry

- Industry involvement in EP PerMed can be envisaged at least at three levels:
 - As part of the EP PerMed Stakeholder group making close and frequent consultations possible at both policy and funding levels
 - In EP PerMed funded projects as active project participants
 - Potentially as co-funders at project level

EP PerMed and industry

- The final model how industry can interact with EP PerMed will have to await the Member States consultations
- There is no doubt that industry is needed in EP PerMed
- EP PerMed seeks, in an open and transparent way, the full engagement and active participation of all relevant industrial players

Thank you for your attention !

- **Contact details of the ICPerMed/ERA PerMed preparatory group:**
- ICPerMed: ICPerMed@dlr.de
- ERA PerMed: ERAPerMed@agencerecherche.fr